Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate the effectiveness of low-dose oral alpha-interferon (alpha-IFN), 247 HIV-infected study subjects received placebo, Alferon LDO, Veldona, or Ferimmune in a randomized, double-blind trial. Subjects had CD4+ counts between 50 and 350 cells/mm3 and HIV-related symptoms at entry. Study subjects rated the severity of eight symptoms using a symptom burden index (SBI). Study endpoints included changes in SBI, weight, CD4+ count, and Karnofsky score between baseline and the 24-week visit. The SBI outcome and weight were measured in 99 and 106 study subjects, respectively, at both the baseline and 24-week visits. Baseline SBI scores ranged from 5.4 to 7.9 in the four arms. No clinically important or statistically significant differences were found among the four arms with regard to SBI or weight change over the 24-week period. There were also no significant differences among the arms for CD4+ cell count and Karnofsky score. Few adverse reactions were noted in any arm, and there were no significant differences between arms. Although the trial was designed to enroll 560 study subjects and was prematurely terminated because of slow accrual and discontinuations of participants, the small differences among the arms in the primary and secondary endpoints do not support claims of efficacy for the measures studied.
 ...
PMID:A multicenter, randomized, controlled trial of three preparations of low-dose oral alpha-interferon in HIV-infected patients with CD4+ counts between 50 and 350 cells/mm(3). Division of AIDS Treatment Research Initiative (DATRI) 022 Study Group. 1063 96

A topical formulation of Interferon alfa-n3 (Alernon N Gel) is in clinical trials for HIV-infected women who are co-infected with human papillomavirus (HPV) and who have persistent cervical dysplasia. A study will compare use of the gel in combination with surgery, versus surgery alone.
 ...
PMID:Topical interferon for HIV-positive women. 1136 68

The National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring a multicenter study to examine the effects of low-dose oral alpha interferon (LDOAI) on the symptoms caused by HIV disease. The four-arm study, to be conducted at 14 sites in the United States, will compare 3 preparations of LDOAI (Alferon LDO, Veldona and Ferimmune), with some patients receiving only placebos. The study, DATRI 022, will recruit 560 HIV-infected people with a CD4+ T cell count between 50 and 350 cells per cubic millimeter of blood. Although large clinical trials have not shown that LDOAI blocks HIV replication or improves immune systems, LDOAI products have been used in the U.S., particularly in African American communities, based on reports of beneficial effects on HIV-related symptoms. A review of all the studies involving LDOAI led the NIAID AIDS Research Advisory Committee (ARAC) and the National Medical Association to request that a clinical trial be conducted.
 ...
PMID:Low-dose oral alpha interferon study opens. 1136 8